<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016206</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-013</org_study_id>
    <nct_id>NCT05016206</nct_id>
  </id_info>
  <brief_title>A Study of the Cardiac Effects of Danicopan in Healthy Adults</brief_title>
  <official_title>A Single Ascending Dose, Randomized, Double-Blind, Double-Dummy, Placebo- and Positive Controlled Study to Evaluate the Effect of ACH-0144471 on the QT Interval in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, double-blind, double-dummy, placebo- and positive-controlled, 2-arm&#xD;
      (Treatment Arm and Control Arm), parallel study to evaluate the effect of ACH-0144471&#xD;
      (danicopan) on the QT interval in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants randomized to the Treatment Arm received all 3 doses of danicopan in a single&#xD;
      ascending fashion over 3 periods (Treatment Sequence ABC). A single oral dose of danicopan&#xD;
      was administered with a moxifloxacin-matching placebo on Day 1 of each period.&#xD;
&#xD;
      Participants randomized to the Control Arm were further randomized to receive 1 of 2&#xD;
      treatment sequences (Treatment Sequences EFG or IJK). A single oral dose of&#xD;
      danicopan-matching placebo was administered with moxifloxacin or with moxifloxacin-matching&#xD;
      placebo, as per the assigned randomization scheme, on Day 1 of each period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Actual">October 12, 2018</completion_date>
  <primary_completion_date type="Actual">October 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This was a double-dummy, placebo- and positive-controlled study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected Change From Baseline In QTc Intervals (ddQTc) For Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Heart Rate (HR) For Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In QT Interval For Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Pulse Rate (PR) For Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In RR Interval For Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In QRS Interval For Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ddQTcF Of Moxifloxacin</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent T-wave Morphology Abnormalities And Pathologic U-waves</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration Versus Time Curve From Time 0 To 24 Hours Post-dose (AUC0-24) Of Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) Of Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach The Maximum Observed Plasma Concentration (Tmax) Of Danicopan</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants Experiencing Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up visit (14 [+/- 2] days after last study drug administration)]</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Arm (ABC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Sequence ABC - Participants received all 3 doses of danicopan in ascending fashion over 3 periods:&#xD;
Treatment A (Period 1): Danicopan 400 milligrams (mg) and moxifloxacin-matching placebo.&#xD;
Treatment B (Period 2): Danicopan 800 mg and moxifloxacin-matching placebo.&#xD;
Treatment C (Period 3): Danicopan 1200 mg and moxifloxacin-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm (EFG and IJK)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received 1 of 2 treatment sequences (Treatment Sequence EFG or Treatment Sequence IJK) over 3 periods:&#xD;
Treatment E (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin-matching placebo.&#xD;
Treatment F (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin 400 mg.&#xD;
Treatment G (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin-matching placebo.&#xD;
Treatment I (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin 400 mg.&#xD;
Treatment J (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin-matching placebo.&#xD;
Treatment K (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin 400 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>Danicopan tablets administered as a single oral dose.</description>
    <arm_group_label>Treatment Arm (ABC)</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin-matching Placebo</intervention_name>
    <description>Moxifloxacin-matching placebo was administered as a single oral dose.</description>
    <arm_group_label>Control Arm (EFG and IJK)</arm_group_label>
    <arm_group_label>Treatment Arm (ABC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan-matching placebo</intervention_name>
    <description>Danicopan-matching placebo was administered as a single oral dose.</description>
    <arm_group_label>Control Arm (EFG and IJK)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin 400 mg was administered as a single tablet oral dose.</description>
    <arm_group_label>Control Arm (EFG and IJK)</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50 kg at screening.&#xD;
&#xD;
          -  Female participants must have been of nonchildbearing potential.&#xD;
&#xD;
          -  Nonsterile male participants must have agreed to abstinence or used a highly effective&#xD;
             method of contraception.&#xD;
&#xD;
          -  No clinically significant history or presence of electrocardiogram findings at&#xD;
             screening and check-in.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of any clinically significant deviation from normal in clinical laboratory&#xD;
             evaluations.&#xD;
&#xD;
          -  History of any medical or psychiatric condition or disease that might limit the&#xD;
             participant's ability to complete or participate in this clinical study, confound the&#xD;
             results of the study, or pose an additional risk to the participant by their&#xD;
             participation in the study.&#xD;
&#xD;
          -  History or presence of drug or alcohol abuse within 2 years prior to first dosing;&#xD;
             current tobacco/nicotine user or a positive cotinine test at screening; positive for&#xD;
             alcohol and/or drugs-of-abuse screen at screening or first check-in.&#xD;
&#xD;
          -  Any previous procedure that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          -  A history of significant multiple and/or severe allergies or had an anaphylactic&#xD;
             reaction or significant intolerability to prescription or non-prescription drugs.&#xD;
&#xD;
          -  Body temperature ≥ 38°Celsius on Day -2 or Day 1 prior to first dosing; history of&#xD;
             febrile illness, or other evidence of infection, within 14 days prior to first dosing.&#xD;
&#xD;
          -  Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives (if known) or 30 days before&#xD;
             first dosing, whichever was longer.&#xD;
&#xD;
          -  Donation of whole blood from 3 months before first dosing, or of plasma from 30 days&#xD;
             before first dosing; received blood products within 6 months before first dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danicopan</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>QT Interval</keyword>
  <keyword>Concentration-QT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

